Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LXRX vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–5 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: LXRX 1 – 4 CAPR (1 Tie) Matrix Metrics: LXRX 5 – 5 CAPR

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While LXRX currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -147.4% operating margin) and revenue trajectory (-7.9% vs. -20.7% YoY).
  • Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both LXRX (38.7/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LXRX vs CAPR
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.51% 1D
Market Cap $810.3M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 0.62β · 60% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 5.0 Fund 33.0 Flow 65.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $1.60 · SMA50: $1.76
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.4 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (LXRX 1 – 4 CAPR)

Columns: Metric · LXRX · CAPR
1. Valuation Multiples CAPR
Forward P/E N/M 78.7x
Trailing P/E N/M 78.7x
PEG Ratio N/M 0.38x
EV / Revenue 21.3x 57.8x
2. Growth & Scale CAPR
Revenue Growth (YoY) -20.7% -7.9%
Earnings Growth (YoY) -63.4% +0.0%
TTM Revenue (USD) $39M $11M
Market Cap $810.3M $595.4M
3. Profitability & Quality CAPR
Gross Margin 91.4% N/A
Operating Margin -147.4% 0.0%
Net Profit Margin -161.8% 0.0%
Return on Equity (ROE) -43.9% -100.5%
4. Balance Sheet & Cash Flow LXRX
Cash Generation (TTM) -$49M -$146M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.5M Net Debt (0.33x D/E) $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 78.4% (8th %ile) 637.1% (89th %ile)
Put/Call OI Skew N/A 1.57x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LXRX (5) vs CAPR (5)
Institutional Metric LXRX CAPR Criterion Row Edge
Market Capitalization
Scale
$810.3M $595.4M Larger Scale LXRX
Trailing P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Forward P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Revenue Growth (YoY)
Growth
-20.7% -7.9% Higher Growth CAPR
Operating Margin (TTM)
Profitability
-147.4% 0.0% Higher Margin CAPR
Net Profit Margin
Profitability
-161.8% 0.0% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-43.9% -100.5% Higher ROE LXRX
52-Week Range Position
Momentum
41% ($1–$3) 15% ($3–$40) Stronger Trend LXRX
Beta / 30D Volatility
Risk Regime
0.62β · 60% Vol 1.52β · 152% Vol Lower Realized Risk LXRX
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 28.0 / 100 (SELL) Higher Composite LXRX
Trailing 12M Revenue (USD)
Operating Scale
$39M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 21.3x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$49M ($9.5M Net Debt (0.33x D/E)) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +11.43 pp
LXRX: +14.8% · CAPR: +26.23%
3M Horizon CAPR +47.52 pp
LXRX: -27.89% · CAPR: +19.63%
6M Horizon LXRX +48.83 pp
LXRX: -21.75% · CAPR: -70.58%
1Y Horizon CAPR +25.61 pp
LXRX: +21.18% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LXRX Revenue CAPR Revenue LXRX Op. Margin CAPR Op. Margin Margin Leader
FY2018 $30M $0M -388.5% -917.0% LXRX
FY2019 $30M $0M 437.5% -769.5% LXRX
FY2020 $20M $0M -204.2% -4412.6% LXRX
FY2021 N/A $0M N/A -8549.9% CAPR
FY2022 N/A $0M N/A -1163.9% CAPR
FY2023 $0M $30M -15473.0% -95.6% CAPR
FY2024 $10M $20M -3284.7% -191.1% CAPR
FY2025 $50M N/A -98.2% N/A LXRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LXRX BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 78.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $810.3M market capitalization and -147.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LXRX vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LXRX currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -147.4% operating margin) and revenue trajectory (-7.9% vs. -20.7% YoY). Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both LXRX (38.7/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAPR leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LXRX cumulative revenue shifted +66.7% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

CAPR screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 21.3x EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.62β · 60% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.